Ozmosi | Collagenase Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Collagenase

Alternative Names: collagenase, santyl, qwo
Clinical Status: Inactive
Latest Update: 2026-02-16
Latest Update Note: News Article

Product Description

COLLAGENASE (kohl LAH jen ace) is an enzyme that breaks down collagen in damaged tissue and helps healthy tissue to grow. It may help wounds heal faster. (Sourced from: https://my.clevelandclinic.org/health/drugs/18678-collagenase-ointment)

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Topical, Injection

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Hong Kong | Hungary | India | Ireland | Italy | Japan | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Peru | Poland | Portugal | Russia | Slovakia | Slovenia | Spain | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Healthpoint
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Collagenase

Countries in Clinic: Austria, China, Germany, Italy, Sweden

Active Clinical Trial Count: 4

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Diabetic Foot|Dupuytren Contracture

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2023-507332-20-00

RR37_23_01

P2

Recruiting

Dupuytren Contracture

2026-07-31

2025-05-02

Treatments

2023-509621-45-00

RRE8_23_01

P2

Recruiting

Unknown

2027-06-03

2025-05-02

Treatments

2022-000666-17

Vibrio alginolyticus collagenase Phase II

P2

Completed

Dupuytren Contracture

2023-11-10

2025-05-06

Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20251247

CTR20251247

P2

Active, not recruiting

Diabetic Foot

None

2026-01-18

Patient Enrollment|Treatments|Trial Status